GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » ROA %

BioDelivery Sciences International (BioDelivery Sciences International) ROA % : 88.02% (As of Dec. 2021)


View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. BioDelivery Sciences International's annualized Net Income for the quarter that ended in Dec. 2021 was $255.6 Mil. BioDelivery Sciences International's average Total Assets over the quarter that ended in Dec. 2021 was $290.3 Mil. Therefore, BioDelivery Sciences International's annualized ROA % for the quarter that ended in Dec. 2021 was 88.02%.

The historical rank and industry rank for BioDelivery Sciences International's ROA % or its related term are showing as below:

BDSI' s ROA % Range Over the Past 10 Years
Min: -100.92   Med: -22.48   Max: 32.31
Current: 32.31

During the past 13 years, BioDelivery Sciences International's highest ROA % was 32.31%. The lowest was -100.92%. And the median was -22.48%.

BDSI's ROA % is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.72 vs BDSI: 32.31

BioDelivery Sciences International ROA % Historical Data

The historical data trend for BioDelivery Sciences International's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International ROA % Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.56 -34.45 -10.50 12.16 30.07

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.43 8.69 14.72 10.54 88.02

Competitive Comparison of BioDelivery Sciences International's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's ROA % distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's ROA % falls into.



BioDelivery Sciences International ROA % Calculation

BioDelivery Sciences International's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=84.86/( (239.894+324.596)/ 2 )
=84.86/282.245
=30.07 %

BioDelivery Sciences International's annualized ROA % for the quarter that ended in Dec. 2021 is calculated as:

ROA %=Net Income (Q: Dec. 2021 )/( (Total Assets (Q: Sep. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=255.56/( (256.07+324.596)/ 2 )
=255.56/290.333
=88.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2021) net income data. ROA % is displayed in the 30-year financial page.


BioDelivery Sciences International  (NAS:BDSI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=255.56/290.333
=(Net Income / Revenue)*(Revenue / Total Assets)
=(255.56 / 172.616)*(172.616 / 290.333)
=Net Margin %*Asset Turnover
=148.05 %*0.5945
=88.02 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


BioDelivery Sciences International ROA % Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.
Executives
James Vollins officer: See Remarks C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd director C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho officer: See Remarks 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey director, officer: Chief Executive Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc director 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha officer: See Remarks 1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr director BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier director, officer: Chief Executive Officer C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith officer: Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612